Literature DB >> 20382686

Genetic variability at the six transmembrane protein of prostate 2 locus and the metabolic syndrome: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study.

Aurélie Miot1, Suliya Maimaitiming, Nathalie Emery, Naima Bellili, Ronan Roussel, Jean Tichet, Gilberto Velho, Beverley Balkau, Michel Marre, Frédéric Fumeron.   

Abstract

CONTEXT: The six-transmembrane protein of prostate 2 (STAMP2) has been shown to be involved in insulin resistance in animal models, but in humans, its role is far from understood. Our hypothesis was that genetic variation of STAMP2 could be associated with insulin resistance phenotypes such as the metabolic syndrome (MetS) in humans.
OBJECTIVE: Our objective was to search for associations between STAMP2 polymorphisms and the MetS in humans. SUBJECTS AND METHODS: Nine single-nucleotide polymorphisms (SNPs) were tested for associations with the International Diabetes Federation-defined MetS and its constituent parameters in 5212 French Caucasians from the prospective study, Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR), with a 9-yr follow-up. Methods included logistic regression and analysis of covariance adjusting for confounding variables and testing for interactions.
RESULTS: None of the SNPs was significantly associated with the prevalence or the incidence of the MetS. The rs12386756 was marginally associated with two parameters of the MetS [triglycerides (P = 0.04) and fasting glucose (P = 0.05)]. An interaction effect between this SNP and fat intake was observed on high-density lipoprotein-cholesterol levels (P = 0.01) and systolic blood pressure (P = 0.03) that is consistent with an interrelation between STAMP2 and nutrition. Three SNPs were associated with insulin levels, but these SNPs were not associated with other features of the MetS.
CONCLUSION: These findings suggest that the common polymorphisms of STAMP2 are unlikely to significantly contribute to the risk of the MetS in the general population, but relationships with insulin and interactions with fat intake need to be replicated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382686     DOI: 10.1210/jc.2010-0026

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  STEAP4 expression in human islets is associated with differences in body mass index, sex, HbA1c, and inflammation.

Authors:  Hannah M Gordon; Neil Majithia; Patrick E MacDonald; Jocelyn E Manning Fox; Poonam R Sharma; Frances L Byrne; Kyle L Hoehn; Carmella Evans-Molina; Linda Langman; Kenneth L Brayman; Craig S Nunemaker
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

2.  Genetic Variants in Six-Transmembrane Epithelial Antigen of Prostate 4 Increase Risk of Developing Metabolic Syndrome in a Han Chinese Population.

Authors:  Yue Qi; Yaqin Yu; Yanhua Wu; Shibin Wang; Qiong Yu; Jieping Shi; Ziqi Xu; Qingqing Zhang; Yingli Fu; Yao Fu; Changgui Kou
Journal:  Genet Test Mol Biomarkers       Date:  2015-10-28

Review 3.  STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper.

Authors:  Rachel T Scarl; C Martin Lawrence; Hannah M Gordon; Craig S Nunemaker
Journal:  J Endocrinol       Date:  2017-06-02       Impact factor: 4.286

4.  The crystal structure of six-transmembrane epithelial antigen of the prostate 4 (Steap4), a ferri/cuprireductase, suggests a novel interdomain flavin-binding site.

Authors:  George H Gauss; Mark D Kleven; Anoop K Sendamarai; Mark D Fleming; C Martin Lawrence
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

Review 5.  STEAP4 and insulin resistance.

Authors:  Xiaoling Chen; Zhiqing Huang; Bo Zhou; Huan Wang; Gang Jia; Guangmang Liu; Hua Zhao
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

Review 6.  STAMPing into Mitochondria.

Authors:  Seong Keun Yoo; JaeHun Cheong; Hye Young Kim
Journal:  Int J Biol Sci       Date:  2014-03-08       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.